Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

KING OF PRUSSIA, PA — Vertex, Inc. (NASDAQ: VERX) has announced robust financial results for the third quarter of 2024, ...

Vertex, Inc. VERX reported better-than-expected third-quarter financial results and raised its FY24 revenue guidance on ...

Stay informed and make strategic decisions with our Ratings Table. Vertex Inc is a provider of tax technology and services. Its software, content, and services help customers stay in compliance with ...

Vertex, Inc. ( (VERX) ) has released its Q3 earnings. Here is a breakdown of the information Vertex, Inc. presented to its investors. Vertex, ...

Jefferies raised the firm’s price target on Vertex (VERX) to $60 from $50 and keeps a Buy rating on the shares. The company posted solid ...

Vertex's growth momentum remains strong, supported by ECC to S/4HANA migration and multi-year ERP upgrade cycle. Read my ...

Fintel reports that on November 4, 2024, Jefferies upgraded their outlook for Vertex (NasdaqGM:VERX) from Hold to Buy.

Latest release includes Pega GenAI enhancements and increased flexibility to accelerate transformation, improve customer and employee experiences, and maximize efficiency CAMBRIDGE, Mass. – October 29 ...

Crispr Therapeutics recently received FDA and EMA approval for Casgevy. Read why CRSP stock is compelling investment in the ...

Vertex has reported phase 3 data on its near-approval pain drug candidate suzetrigine, shedding light on how the non-opioid painkiller combines with ibuprofen and why the prospect failed to match ...

1 Day VERX 0.35% DJIA 0.09% S&P 500 0.40% Business/Consumer Services -0.03% ...